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The alveoli of mammalian lungs are covered in a thin lipid film referred to as 
pulmonary surfactant. The primary purpose of pulmonary surfactant is to reduce the 
surface tension of the air/liquid interface allowing breathing with minimal effort required.  
We investigated the effect of addition of cholesterol and amyloid-β peptide on 
structure and function of Bovine Lung Extract Surfactant (BLES) and model lipid films.  
In our first experiment, we have demonstrated the effect of amyloid-β and 
cholesterol on lipid films of DPPC, DPPC-DOPG and BLES. We saw that cholesterol 
inhibits multilayer formation in all monolayers. Amyloid-β increases multilayer 
formation in DPPC and DPPC-DOPG, but reduced multilayer formation in BLES. When 
cholesterol and amyloid-β is added to BLES, 1% amyloid-β is inconsequential, whereas 
10% amyloid-β allows BLES to regain some of its surfactant function. 
In our second experiment, we observed that for bothanionic DOPG and cationic 
DOTAP films which are in the fluid phase, amyloid-β interacts with the  bilayer much 
quicker than in zwitterionic DPPC which is in the gel phase. Approaching 24 hours, we 
see small fibrils form on the bilayer, but these fibrils are considerably smaller than those 
formed when amyloid-β is incubated in solution. For fluid phase bilayer membrane, 
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Chapter 1  
Introduction 
 
1.1 The Pulmonary Surfactant System 
1.1.1. Introduction to the Pulmonary Surfactant System 
 Pulmonary surfactant is a complex protien-lipid mixture that forms a monolayer 
existing in mammalian lungs and serves to reduce the surface tension of the air/liquid 
interface to reduce the work required of breathing.  
Pulmonary surfactant is by definition a lipid detergent, usually consisting of a 
mixed lipid-protein monolayer lining the alveoli in the air/liquid interface. The primary 
purpose of surfactant is to lower the surface tension of this interface to near zero values 
(Holm, Enhorning and Notter 1988). Experimental measurements indicate that the 
equilibrium surface tension is approximately 23 mN/m at beginning of expiration (Floros 
2005). While this low surface tension is necessary to allow minimal effort while 
breathing, surfactant must change its properties during the breathing cycle to increase its 
surface tension to a higher value to prevent alveolar collapse (Clements 1957). 
 Surfactant is secreted by exocytosis from the lamellar bodies which are formed by 
alveolar type II cells in the lung epithelium. Tubular myelin is a complex of bilayer 
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1.1.2. Composition of the Pulmonary Surfactant System 
Pulmonary surfactant is primarily a lipid-based system with small amounts of associated 
proteins referred to as the surfactant proteins A, B, C, and D, named in order of their 
discovery. Historically surfactant has been considered a lipid monolayer, but this idea is 
now seen as an oversimplification (Johannsen 1997). The composition of surfactant can 
vary and is influenced by diet, age, and physical fitness (Crewels, van Golde and 
Haagsman 1997).  
1.1.2.1. Lipids 
The primary lipid (70-80%) in pulmonary surfactant has been shown to be 
phosphatidylcholine (PC), in which 50-70% is saturated PC (Crewels, van Golde and 
Haagsman 1997). Of this PC lipid layer, dipalmitoylphosphatidylcholine (DPPC) is 
considered the primary variant lipid. DPPC is capable of reducing surface tension levels 
approaching zero; however, DPPC alone fails as an effective surfactant because it is slow 
to re-spread when compression is relieved and it is slow to adsorb from an aqueous 
suspension (Poulain and Clements 1995).  DPPC molecules in a monolayer are oriented 
with the fatty acid tails pointed up (towards the air interface). The polar headgroups are in 
the subphase with the fatty acid tails tilted between 21.5-29 degrees depending on 
humidity (Katsaras, Yang and Epand 1992). In order for lung surfactant to maintain its 
biophysical properties, the lipids are required to both allow the surfactant surface tension 
to reduce to very low values, as well as re-spread rapidly during the respiratory cycle. 
The individual components of surfactant are each good at lowering surface tension 
(DPPC) or fluidizing the monolayer (PG, PC, proteins); none of the individual 
components exhibits both properties (Ding, et al. 2001). 
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1.1.2.2. Proteins 
Within the pulmonary surfactant system proteins compose approximately 10% of 
the surfactant system (Johansson, Curstedt and Robertson 1994). These proteins serve a 
variety of roles within the surfactant system. The surfactant proteins can be divided into 
two classes: the hydrophilic proteins and the hydrophobic proteins. 
 The first protein identified was the hydrophilic Surfactant Protein A. SP-A 
consists of 248 amino acid residues and has a molecular weight between 28-36 kDa 
depending on the species (Crewels, van Golde and Haagsman 1997). The following is a 
list of function which SP-A is responsible for (Crewels, van Golde and Haagsman 1997): 
1. Formation of tubular myelin 
2. Regulation of phospholipid insertion into the monolayer 
3. Modulation of uptake and secretion of phospholipids by type II cells 
4. Activation of alveolar macrophages 
5. Binding and clearance of bacteria and viruses 
6. Chemotactic stimulation of alveolar macrophages. 
The other hydrophilic surfactant protein is SP-D. There is some academic debate over 
whether SP-D is a true surfactant protein since it is also found in gastric tissue (Crewels, 
van Golde and Haagsman 1997). SP-D is the largest of the surfactant proteins consisting 
of 355 amino acid residues and having a molecular weight of 43 kDa. Along with SP-A, 
SP-D plays an important role in pathogen defense, which is its primary purpose (Crewels, 
van Golde and Haagsman 1997).  
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 The surfactant proteins B and C (SP-B, SP-C) are hydrophobic proteins. Both SP-
B and SP-C are considerably smaller than SP-A and SP-D with SP-C containing 35 
amino acid residues. In addition, both SP-B and SP-C are only soluble in organic 
compounds such as chloroform or methanol (Perez-Gil 1993). Both SP-B and SP-C 
require intracellular post translational modification to form their mature forms (Beers, et 
al. 1994). Specifically, SP-C needs to gain two thio-ester side chains in order to maintain 
its biophysical properties (Johannsen 1997). SP-B is high in cysteine which allows it to 
form a unique pattern of disulfide bonds to assist in stabilizing the protein. The most 
important property of SP-B is in enhancing the biophysical properties of the surfactant 
and assisting in rapid insertion of phospholipids into the air/liquid interface. This results 
in a stable surface film (Hawgood, et al. 1987). SP-C has similar roles in the maintenance 
of surfactant as SP-B: it is responsible for rapid formation of the monolayer and 
molecular ordering of the monolayer. These roles require SP-C to have extreme structural 
and stability properties (Johannsen 1997). SP-C is one of the most hydrophobic proteins 
discovered: this hydrophobicity is the result of a significant portion of the protein being 
made up of the highly hydrophobic amino acid valine resulting in an alpha-helical stretch 
which spans the DPPC layer (Morrow, et al. 1993). NMR studies of SP-C confirm that 
SP-C has no tertiary structure (Johannsen 1997). SP-C is also the only surfactant protein 
that lacks homologous proteins. SP-C contains two palmitoyl groups post-translationally 
bound to two amino acid residues. This palmitoylation of SP-C increases membrane 
affinity of the protein, influences protein structure and plays a role in membrane fusion 
by enhancing re-spreading and stability of DPPC (Qanbar 1996). 
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1.1.3. Function of Pulmonary Surfactant 
The primary function of the pulmonary surfactant system is to reduce the surface 
tension of the air/liquid interface to near zero at the beginning of expiration. No single 
component of surfactant contributes solely to the required biophysical properties 
necessary for effective surfactant function (Ding, et al. 2001).  The tension of the surface 
film varies with area, where exhalation results in decreased surface area and decreased 
surface tension, preventing the alveoli from collapsing (Clements 1957). The pressure 
within the alveoli can be estimated by the expression, 
     P = 2γ/r,     
where P is the pressure, γ is the surface tension and r is the radius of the alveoli (King 
1982). Knowledge of individual surfactant components will assist with understanding 
how the complete surfactant system operates. As mentioned earlier, surfactant is 
composed primarily of phospholipids. These phospholipids include phosphatidylcholine 
(saturated and unsaturated), primarily dipalmitoylphosphatidylcholine (DPPC) and 
phosphatidylglycerols (PG). A mixture of these lipids is necessary to make up the lipid 
portion of an effective surfactant. These two lipids have different characteristics. During 
the breathing cycle, DPPC is required to lower the surface tension of the air/liquid 
interface (Clements 1964). While DPPC is effective in lowering surface tension, it is 
inadequate to complete the task of respreading the surfactant into an even lipid layer; PG 
on the other hand is effective in spreading this surfactant (Hallman 1975). Incidentally, 
PG is one of the last compounds developed during natal development. A premature infant 
is often born without sufficient PG. This lack of PG is causal to Infant Respiratory 
Distress Syndrome (Hallman 1975).  
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 The process of lowering the surface tension in surfactant films is accelerated 
when surfactant proteins are included in the lipid film (King 1972). A good lung 
surfactant will adsorb within milliseconds during a deep breath. During expiration, when 
the surface film is compressed and below the equilibrium surface tension, there is a net 
desorption of various components from the film (King 1972). A given material in the 
alveolar subphase will not integrate into the air/liquid interface unless surfactant surface 
tension is below the equilibrium value for the material (King 1972). SP-A acts together 
with SP-B and SP-C to promote rapid formation of the surfactant film (Rooney, Young 
and Mendelson 1994). Surfactant protein B reduces surface tension by increasing the 
lateral stability of the phospholipid monolayer (Cochrane and Revak 1991). It has been 
shown by Mathialagen et al that SP-B is more influential in reducing surface tension than 
SP-C, suggesting that SP-B is more efficient in removing unsaturated phospholipids 
(which inhibit the reduction of surface tension) from the surfactant surface (Mathialagan 
1990). As mentioned earlier, SP-C contains two palmitoyl groups post-translationally 
bound to cystienes 5 and 6. This palmitoylation of SP-C increases membrane affinity of 
the protein, influences protein structure, and plays a role in membrane fusion by 
enhancing re-spreading and stability of DPPC (Qanbar, et al. 1996). SP-C is also 
responsible for maintaining lipids in the vicinity of the air/liquid interface. Meanwhile 
SP-B assists in ordering monolayer collapse, ensuring a reduction in surface tension 
(Ding, et al. 2001). 
 While the surfactant proteins assist in the function of surfactant, the serum 
proteins (or blood proteins) inhibit the function of surfactant. The presence of serum 
proteins in the surfactant has been shown by Holm, et al to increase surface tension by up 
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to a factor of two. These results suggest that these proteins may be mechanistically 
responsible for limiting effective surfactant function (Holm, Enhorning and Notter 1988).  
 As stated earlier, effective surfactant must be able to change its properties during 
the breathing cycle: surfactant must have a very low surface tension at the beginning of 
expiration to allow oxygen diffusion, and then surface tension must increase at the end of 
expiration to prevent alveolar collapse. The explanation of the method by which 
surfactant accomplishes this remarkable task has evolved over the course of surfactant 
research. It was previously thought that as the surface area of the alveoli decreases 
(during expiration), the surfactant must “squeeze-out” unsaturated lipids and proteins 
(Ding, et al. 2001). This would lead to a surfactant rich in DPPC, resulting in an increase 
in surface tension preventing alveolar collapse. These “squeezed-out” components would 
temporarily reside in microscopic “reservoirs” on the phospholipid layer. During 
inspiration, the components within the reservoirs would be released and spread along the 
air/liquid interface. It was theorized that SP-C stabilized these reservoirs (Amrein, von 
Nahmen and Sieber 1997) by incorporating their alpha helix into one bilayer and 
stretching their palmitoyl groups into neighboring bilayers. Through the use of atomic 
force microscopy (AFM), Ding et. al have expanded on this “squeeze-out” theory and 
somewhat rendered it obsolete. In fact, during expiration, the lipid monolayers form 
multiple, discrete layers to compensate for the reduction in alveolar surface area (Ding, et 
al. 2001). Therefore, these other components are not “squeezed-out”, but rather they 
remain at the surface and fold and “unzip” in order to maintain low surface tensions and 
re-spreading readily at the collapsed state without changing surfactant composition. 
Proteins located within the phospholipid folds may provide a method of incorporating 
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new material into the air/liquid interface upon alveolar expansion (Ding, et al. 2001). The 
research conducted by Oosterlaken, et al indicates that the insertion rates of lipids into the 
monolayer were not affected by the composition of the monolayer, but only affected by 
the protein content (Oosterlaken 1991). Furthermore, because of surface pressures can be 
reduced to very low values without loss of proteins from the monolayer, it can be 
concluded that there is a lipid/protein interaction (Oosterlaken 1991).  
1.1.4. Relevant Pathologies 
Acute Respiratory Distress Syndrome (ARDS) is a respiratory condition resulting 
from pulmonary surfactant failure. This failure can be attributed to a number of factors 
including: presence of serum (blood proteins) within the alveoli (perhaps as a result of an 
acute lung injury), amyloidosis of the surfactant protein C, as well as other unknown 
factors. Research by Gregory et al showed that the presence of serum proteins within the 
air/liquid interface may cause ARDS (Gregory, et al. 1991) by changing the chemical 
composition and function of pulmonary surfactant (Holm, Enhorning and Notter 1988). 
This failure of lung surfactant occurs when the surfactant fails to adequately reduce the 
surface tension of the air/liquid interface. A by-product of this surfactant failure is 
considerably lower lung surface, responsible for gas exchange (Petty, et al. 1979).  
Mortality for patients suffering from ARDS remains high. ARDS typically 
requires replacement surfactant therapy (Floros 2005). This surfactant may be either a 
natural animal extract, such as Bovine Lung Extract Surfactant (BLES) or an artificial 
surfactant made up of DPPC, PG, and various surfactant proteins, which is currently 
under development and is an active area of research. In addition, the use of the coagulant 
antithrombin III, as a treatment for ARDS, is being investigated (Floros 2005). This is 
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because the presence of the serum protein fibrinogen destroys surfactant activity because 
it initiates the coagulation cascade. However, lysis of the clot allows surfactant function 
to be restored (Floros 2005).   
Neonatal Respiratory Distress Syndrome (RDS) is similar to ARDS, except that it 
occurs in premature infants where surfactant is not development. In fact, ARDS used to 
be an acronym for Adult Respiratory Distress Syndrome to distinguish it from the infant 
version. NRDS is usually caused by pre-term births or a genetic condition. Since, the 
pulmonary system is the last mammalian system to develop during gestation, it stand’s to 
reason that the pulmonary system is the system most affected by a pre-term birth. 
Specifically, the surfactant system is among the last to develop within the pulmonary 
system. Typical treatment of RDS is artificial surfactant or BLES therapy. Breathing is 
assisted through the use of a high frequency oscillating ventilator which provides 
sufficient oxygen to the lungs, while keeping tidal volume low and peak end expiratory 
pressure (PEEP) within acceptable limits. If a pre-term birth is expected, the mother is 
given various hormones to assist with fetal surfactant biosynthesis (Floros 2005). 
Various genetic disorders may also result in IRDS. Nogee, et al observed SP-C 
mutation in infants with chronic lung disease. This mutation would result in a decrease in 
lipid stability compromising surfactant function (Nogee, et al. 2002). Nogee also 
discovered that a frameshift mutation in the gene producing SP-B resulted in no SP-B 
production and 100% infant mortality of those infants suffering from this genetic disorder 
(Nogee, et al. 2002).  
 Another disorder, known as Pulmonary Alveolar Proteinosis (PAP) is 
associated with the amyloidosis of SP-C. Pulmonary Alveolar Proteinosis is the result of 
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the surfactant protein C forming amyloid fibrils under certain conditions (Gustafsson, et 
al. 1999) (Dluhy, et al. 2003).  The structure of these fibrils is similar to fibrils formed by 
other amyloid proteins, such as amyloid-β and α-synuclein. When SP-C plaques form, 
SP-C ceases to function as an effective distributer of DPPC and leads to a breakdown of 
the effective function of the surfactant (Wüstneck 2004). It appears that this SP-C 
amyloidosis occurs at high lipid/protein concentrations. This condition is a contributing 
factor in (ARDS). 
1.1.5. Current Developments in Research 
The latest developments in surfactant research have revolved around the role of 
cholesterol and electrostatic interactions between protein and lipid. In 2005, Gunesakara 
et al reported that cholesterol is very influential in molecular ordering of the surfactant 
films, even at low concentrations (Gunasekara, et al. 2005). Using atomic force 
microscopy and Kelvin probe force microscopy, Leonenko et al reported that BLES with 
significantly elevated levels of cholesterol (20%) had considerably smaller tip/film 
adhesion forces than BLES with regular (5%) levels of cholesterol. This evidence 
suggests that the adhesive properties of the film were changed by the additional 
cholesterol. In this case, one can assume that with the addition of cholesterol, the lipid 
molecules are not mobile enough to easily rearrange and fold into lipid multilayers. In 
this case, the surface tension is higher on contraction. Furthermore, it is believed that if 
the conversion from lipid monolayer to lipid bilayer is inhibited by cholesterol, the 
unsaturated lipids are unable to form a bilayer and thus are unable to reduce the surface 
tension. This increased concentration of cholesterol results in the lipid film collapsing 
during alveolar compression (Leonenko, Gill, et al. 2007). Studies conducted using 
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Kelvin Probe Force Microscopy (KPFM) have provided further insight into the lipid 
monolayer to bilayer conversion. KPFM has shown that the second layer of the surfactant 
film has a more positive surface potential than the first monolayer while the third layer 
has the same surface potential as the first layer (Leonenko, Rodenstein, et al. 2006).  
1.2 Amyloidosis 
1.2.1. Introduction to Amyloidosis 
Amyloidosis is defined as an abnormal process in which a protein, which is 
normally in an alpha-helical state unfolds, re-conforms in a β-sheet conformation and 
aggregates to form insoluble fibril-like formations (Serpell 2000). These amyloid fibrils 
are then deposited either systemically or in specific organs, destroying surrounding cells 
(Johannson 2005). Amyloid fibrils can be observed by staining with the Congo Red dye 
and showing birefringence under polarized light. They will appear as 5-10 nm fibrillar 
structures detectable by electron microscopy or x-ray diffraction (Serpell 2000). Despite 
significant research into the amyloidosis process, no clear reason has emerged on the 
formation and kinetics of this process (Carrell and Gootu 1998). This amyloidosis 
process is implicated in at least twenty different pathologies, each one affected by the 
aggregation of a different protein. These diseases include the neuro-degenerative 
disorders Alzheimer’s, Huntington's, Parkinson's, and Creutzfeld-Jacob's. Pulmonary 
Alveolar Proteinosis (PAP) is believed to be caused by the amyloidosis of the Pulmonary 
Surfactant Protein C (SP-C) (Johannson 2005).  Whether this fibril formation is causal to 
the pathology or whether this amyloidosis is the result of an abnormal intra-alveolar 
metabolism has yet to be determined (Johannsen 2003). 
 
- 12 - 
 
1.2.2. Amyloid-β 
Amyloid-β is a 40-43 amino acid length peptide, part of the protein associated 
with Alzheimer’s disease. Amyloid-β is a proteolytic product of the Amyloid Precursor 
Protein (APP). Amyloid- β consists of a hydrophilic, extracellular region located at 
residues 1-28, and a hydrophobic, transmembrane alpha-helical coil at residues 29-42 
(Bokvist, et al. 2004).  
The gene for APP is found on chromosome 21, and is expressed in a variety of cells the 
glial, endothelial, epithelial and spleen. The symptoms of Alzheimer’s disease are as a 
result of APP being expressed in neuronal cells (Bokvist, et al. 2004). The function of 
APP is unknown at this point, but past research has suggested that APP may have a role 
as an autocrine factor to stimulate the proliferation of ce11 (Saitoh, et al. 1989), and as a 
modulator of ce11 adhesion. Once amyloid-β is cleaved from APP, it is a soluble 
monomeric peptide in an aqueous environment, and is removed (in healthy persons). In 
pathological cases, amyloid-β may aggregate to a certain degree to become neurotoxic 
(Bokvist, et al. 2004).  
In Alzheimer’s disease, amyloid-β misfolds to form amyloid fibrils. It is believed 
that these amyloid fibrils and their intermediates are causal to the symptoms found in 
patients with AD (Selkoe 2000). Several mechanisms have been suggested as to why 
amyloidosis results in specific pathologies. Research by Lin and associates indicates that 
oligomeric amyloid-β forms ion channels in lipid membranes resulting in higher levels of 
intracellular calcium (Lin, Bhatia and Lal 2001). Perturbations in membrane fluidity have 
been suggested by groups Kremer (Kremer, Pallitto, et al. 2000)and Muller (Muller, et al. 
1998). Free radical production has been suggested by Butterfield (Butterfield, 
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Varadarajan and Koppal 1999) . Changes in lipid metabolism have been suggested by 
Koudinov (Koudinov, Berezov and Koudinova 1998). 
1.2.3. Mechanisms of Action 
Although much research has been conducted on the conformational change of 
Amyloid-β a clear answer still eludes the research community. Amyloid-β fibril 
formation has been shown to involve an α-helix to β-sheet transition. However, not all 
 
Figure 1 - Possible pathways in amyloid fibril formation adapted from (Giurleo, He and Talaga 2008) 
 
protein’s form amyloid deposits by this conformational change. α-synuclein has no 
defined structure in its native state, yet still forms amyloid fibrils (Johannsen 2003). 
Certain proteins show very similar secondary structures once amyloid process is 
Amyloid Pathways 
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complete despite radically different primary structures: this suggests that the amyloidosis 
process for each different protein involves a different biochemical mechanism (Booth, et 
al. 1997). In solution, amyloid-β readily transforms into a β-sheet conformation 
(Szyperski, et al. 1998) despite that molecular dynamics simulations show that the helix 
is highly resistant to unfolding (Kovacs, et al. 1995). Figure 2, shown below, shows a 
schematic of the process of fibril formation. Structure N is the native state and Structure 
U is a completely unfolded state. Structure I is the intermediary state which undergo a 
conformational transition to a  β-sheet structure (O). These β-sheets form protofibrils 
which aggregates to form amyloid fibrils. The electron micrograph depicts the fibrils. The 
scale bar represents 50 nm (Johannsen 2003).  
 
Figure 2 - Proposed mechanism for amyloid fibril formation adapted from 
(Johannsen, Molecular determinants for amyloid fibril formation: lessons from 
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1.2.4. Amyloid Fibrils 
Amyloid fibrils have been shown to associated with a wide variety of diseases 
including Alzheimer’s, Parkinson’s, the prion disease and about 20 others disease of 
various severity. Despite a similar end product, there seems to be no commonality among 
primary protein structure linking these proteins. 
The original work done on amyloid fibril structure stretches back to 1935, when 
Astbury, using x-ray diffraction, found that there existed a difference in length and width 
of egg white when stretched, suggesting a fibre like structure (Astbury and Dickinson 
1935). Later, researchers were able to obtain a cross-β x-ray diffraction pattern. This 
structure was found in the deposits of pathological tissues (Sunde and Blake 1997). 
Today, various methods including x-ray diffraction, NMR, atomic force microscopy, and 
electron microscopy have shown that fibrils formed by different properties share similar 
properties, including a structure made up of unbranched protofilaments (Nelson 2006). 
The classical biophysical definition of an amyloid fibril is a protein structure which 
exhibits red-green birefringence when exposed to circularly polarized light. Identification 
of amyloid fibrils is also made by determining binding to Congo red or Thioflavin T. X-
ray diffraction patterns of amyloid fibrils show characteristic signals produced at 4.7 and 
10 angstroms corresponding to interstrand and stacking distance between the β-sheets. 
Amyloid fibrils are approximately 100 Å in diameter and composed of 20–35 Å wide 
protofilaments.  
  While amyloid-β has a poorly defined monomeric structure due to its insolubility 
and difficulty in crystallization, recent advances have allowed researchers to solve the 
structure of amyloid fibrils (Luhrs, et al. 2005). However, to date, only one amyloid-β 3D 
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structure has been resolved (Nelson 2006). There is general agreement amongst (Nelson 
2006) that amyloid-ߚ peptides have a β sheet secondary structure which stack in an anti-
parallel fashion to form β sheets which run perpendicular to the fibril axis (Kirchner, 
Abraham and Selkoe 1986). Figure 3-Model of β sheet amyloid structure adapted fromA 
shows the Van der Waals interactions between β sheets while Figure 3B and C shows the 
position of the β sheets relative to the direction of the fibril. 
 
Figure 3-Model of β sheet amyloid structure adapted from (Jimenez, et al. 2002) 
These sheets appear to form from amino acid sequences 18-26 and 31-43 (Luhrs, et al. 
2005). Intermolecular interactions amongst the side chains are formed between the odd-
numbered residues of strand 1of the nth molecule and the even-numbered residues of 
strand 2 of the (n -1)th molecule (Luhrs, et al. 2005). These anti parallel sheets are held 
together by hydrogen bonds. All fibrils have been shown to form a left handed helix 
(Bauer, et al. 1995), (Goldsbury, et al. 1997), (Ionescu-Zanetti, et al. 1999), (Harper, 
Liber and Lansbury 1997). Figure 4 - Model of Amyloid Fibril adapted fromFigure 4 - 
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Model of Amyloid Fibril adapted from shows a model of an amyloid-β fibril. Notice the 
anti-parallel β sheet structure stacked together to form a protofilament. Four 
protofilaments are wrapped together to form a mature amyloid fibril. 
 
Figure 4 - Model of Amyloid Fibril adapted from (Jimenez, et al. 2002) 
 
While all fibrils have similar morphologies and properties, small variations in 
structure occurs in amyloid fibrils of different proteins (Balbirnie, Grothe and Eisenberg, 
2001) (Diaz-Avalos, et al. 2003) (Petkova, et al. 2005). Even within the same 
preparations, fibril morphology can vary. This difference has been attributed to the 
number of protofilaments found in the amyloid fibril (Jimenez, et al. 2002). Research by 
Jimenez suggests that individual protofilaments, are relatively flat as opposed to being 
highly twisted as previously suggested (Jimenez, et al. 2002). Comparing various fibrils 
structures suggests that small local changes in β-sheet twist are important in the long 
range coiling of protofilaments (Jimenez, et al. 2002).  
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Work by Nelson has provided the first truly atomic model of the amyloid fibril 
(Nelson, Sawaya, et al. 2005). In this research,  
Nelson, et al showed that side chains protruding from the two sheets forms a tight, 
dry, “steric zipper”. Figure 5-Proposed Atomic Model of Β sheet interactions adapted 
from  Notice the difference between wet and dry interfaces. 
Side chains from each strand nestle between side chains from the opposing sheet. 
This is referred to as the “dry” interface. In this interface, van der Waals interactions hold 
the sheets together, while hydrogen bonds bind neighbouring molecules in the same 
sheet. Disruption of this “steric zipper” may be a target for future drug therapy. In the 
Figure 5-Proposed Atomic Model of Β sheet interactions adapted 
from (Nelson, Sawaya, et al. 2005) 
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“wet” interface, water molecules line neighbouring sheets. Within each sheet, hydrogen 
bonds hold together each segment to its neighbouring segment, through stacks of the 
backbone and side chains, demonstrating the stability of these fibril structures.  
Present research has not yet identified one single theory explaining all the 
properties of amyloid fibrils. However, some models do answer many of the properties of 
the different fibrils (Nelson 2006).  The major recent models of fibril formation are the 
refolding model, natively disordered model, and the gain of interaction model (Nelson 
2006). In the refolding model, it is assumed that the peptide is either in the native or fibril 
form. In this model, the peptide must completely unfold from its native state and refold 
into its fibril form. In this model, the sequence of side chain interactions are unimportant. 
In the natively disordered model, it is assumed that certain proteins are naturally 
disordered in their native state. It is this disordered section of the protein that forms the 
cross-β spine of the amyloid fibril. The third class of model is the gain of interaction 
model. This model hypothesizes that the conformational change in a certain area of the 
peptide exposes a previously unexposed surface. It is this newly exposed surface that 
binds to another molecule and allows the fibril to continue its growth. 
1.2.5. Factors Affecting Fibril Formation 
A number of factors have been identified in increasing the kinetics of 
conformational change in amyloid forming peptide. Jimenez and colleagues showed that 
low pH increases the rate of amyloid fibril formation (Jimenez, et al. 2002). Also, the 
presence of ions, the protein-lipid ratio, and the presence of cholesterol and gangliosides 
have been shown to affect the rate of fibril formation (Maltseva, et al. 2005). Lastly, 
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extensive studies have shown the effect of lipids in amyloid fibril formation (Bokvist, et 
al. 2004). 
1.3 Lipid-Protein Interactions 
1.3.1. Amyloid-Β Membrane Lipid Interactions 
For most amyloid forming proteins associated with amyloid diseases, neither the 
reason for unfolding and aggregation, nor the specific function is known. Most research 
looking into the protein misfolding problem has been conducted in solution. However, 
researchers have recently been investigating the effect of membrane lipids on the protein 
misfolding problem. 
One of these attempts is described by Bockvist and colleagues, who have 
identified two methods in which amyloid-β interacts with lipid membranes (Bokvist, et 
al. 2004). The first is method is that of peptide insertion into the lipid membrane, the 
second method occurs when aggregated amyloid-β binds to the membrane lipid.  
In the first case, Bockvist showed that because of electrostatic interactions, 
peptide insertion increases as the charge of the lipid membrane decreases: maximum 
insertion occurs with negatively charged lipid membranes. This electrostatic effect 
augments the hydrophobic effect where the α-helical section of the peptide wants to insert 
itself into the bilayer. This finding correlates well with research by Maltseva, who 
showed that electrostatic interactions with negatively charged lipids increases peptide 
adsorption and other hydrophobic surfaces (Maltseva, et al. 2005) and Ege, who proposed 
that the strong electrostatic interaction between the peptide and the negatively charged 
lipids, drives the peptide deep into the lipid membrane (Ege and Lee 2004). However, 
amyloid-β has difficulty incorporating into lipid bilayers at high surface pressures (Ege 
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and Lee 2004). When incorporated into the membrane bilayer, amyloid-β peptide is 
stabilized and somewhat prevented from aggregating as it is bound in the membrane; 
amyloid fibril formation is therefore somewhat inhibited (Bokvist, et al. 2004). 
Using a Langmuir Blodgett trough, Ji and associates measured the level of 
amyloid-β insertion into lipid monolayers (Ji 2002). Ji found that both cholesterol and 
low pH increase amyloid-β insertion into the lipid monolayers. Ji hypothesized that 
amyloid-β insertion is partial to lipid rafts which have been found to have higher than 
normal concentrations of cholesterol. Research by Ege and associates (Ege and Lee 2004) 
demonstrates that as lipid packing density increase, peptide insertion into lipid 
monolayers decreases proportionally. While there is general agreement that amyloid-β 
peptides prefer to bind with anionic lipids, research by Ege suggests that cationic lipids 
can bind just as readily. Also, Ege has noted that oligomeric forms of amyloid-β inserts 
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Figure 6 - Schematic model of Amyloid-β interacting with Membranes adapted from (Bokvist, et al. 2004) 
The second mechanism identified by Bockvist occurs where amyloid-β is allowed 
to misfold into β-sheets in bulk solution and then forms amyloid fibrils. In this case, the 
presence of acidic lipids causes an increase in the surface concentration of the amyloid-β 
peptide increasing the conversion rate from α-helix to β-sheet through a direct membrane 
surface interaction (Bokvist, et al. 2004). In this case, amyloid-β is associated with ion 
channel activity resulting in neuronal apoptotic cell death. In this case, it has been shown 
by Maltseva that the β-sheets are oriented parallel to the surface (Maltseva, et al. 2005). 
Bockvist Model of Two Methods of 
Amyloid Aggregation 
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Using circular dichroism and caloimetry, Terzi (1994) suggested a lipid induced 
peptide aggregation of amyloid-β at the membrane of anionic lipids as opposed to 
membrane penetration. The theory proposed by Terzi is that the anionic lipids attract the 
cationic amyloid-β peptide to the surface electrostatically creating a parallel alignment of 
the peptide chains.  
It has been proposed that monomeric amyloid-β may reinsert itself into the 
membrane as a possible mechanism to prevent aggregation and oligomerization (Ji 2002). 
1.3.2. Effect of Membrane Lipids on Amyloidosis 
Research has shown that the amyloidosis process is influenced by membrane 
lipids, especially negatively charged lipids (Maltseva, et al. 2005). In solution, amyloid-β 
reaches a reversible equilibrium of random coil, β sheet structures. Conversely, research 
by Terzi, has demonstrated that in the presence of negatively charged membrane lipids, 
this random and coil-β sheet equilibrium shifts almost completely toward the β sheet 
conformation. It was hypothesized by Terzi that this equilibrium shift is a result of the 
cationic amyloid-β peptide being attracted to the anionic lipids in the membrane forming 
a higher local surface concentration of the peptide on the surface. A combination of an 
increased surface concentration with the aligning of the peptide creates ideal conditions 
for the formation of amyloid fibrils. This process may act as a catalyst, reducing the 
activation energy required to correctly position the peptide chains, or the membrane shifts 
the thermodynamic equilibrium to favour β sheet conformation (Terzi 1994). Another 
theory proposed by Terzi (Terzi 1995) suggests that amyloid-β inserts into the 
hydrophobic region of the lipid membrane and forms β sheets within that region. This 
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possibility is supported by the observation that the membrane mimicking solvent 
trifluoroethanol induces a β-sheet structure. Further research by Choucair (Choucair, et 
al. 2007) provides evidence to the membrane mediation of fibril formation. In their 
research, Choucair and associates used a combination of atomic force microscopy and 
fluorescence to elucidate the effects of membranes on fibril formation. During the course 
of this research Choucair found that when the amyloid-β peptide is added to the lipid, the 
peptide started to accumulate on the lipid bilayer within 15 minutes, compared to the time 
of greater than 1 hour for the peptide to aggregate in solution. Choucair also found no 
evidence of the amyloid-β peptide inserting into the lipid bilayer. 
Work by Choucair, et al shows that amyloid-β fibrils bind preferentially to gel-
phase domains (Choucair, et al. 2007). While considerable research shows that amyloid-β 
binds preferentially to anionic lipids, Kremer demonstrates that amyloid-β changes 
membrane fluidity equally amongst different lipids (Kremer 2001) (Kremer, Sklansky 
and Regina, Profile of Changes in Lipid Bilayer Structure Caused by Beta-Amyloid 
Peptide 2001). Using neutron diffraction, Dante demonstrated that the amyloid section 
25-35 deeply penetrates the lipid bilayer resulting in a perturbation of the bilayer (Dante, 
Hauss and Dencher 2003). 
 Research by Bockvist shows that the presence of acidic lipids electrostatic forced 
between the peptide and the lipid membrane keeps the peptide in a transmembrane 
position, thereby preventing aggregation (Bokvist, et al. 2004).  
Our research is based on the following hypotheses: a) lipid surfaces and their 
structural and electric inhomogeneity play an important role in amyloid fibril formation; 
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b) structure and physical properties, which define function of the surfactant film may be 
considerably changed by fibril association. To test these hypotheses, changes in structural 
properties and surface activity of surfactant films and lipid films upon amyloid 
fibrillization are investigated in model lipid monolayers, bilayers, and BLES surfactant 
films. We believe that non-uniform nanoscale structure (both multilayers visible in AFM 
and non-uniform surface potential distribution discovered by KPFM) of BLES surfactant 
affect the effectiveness of SP-C fibril formation and fundamentally determine their 
interaction with the pulmonary surfactant film. The goal of this research is to investigate 
the structure and physical properties of model lipid monolayers and BLES surfactant 
films upon amyloid fibril formation on the lipid films, using atomic force microscopy 
(AFM) and Kelvin probe force microscopy (KPFM) to elucidate how non-uniform 
morphology and surface potential affects molecular mechanisms. 
1.4 Methods 
1.4.1. Atomic Force Microscopy 
Atomic Force Microscopy (AFM) is a form of Scanning Probe Microscopy and 
was invented in the early 1980’s. The developers of the Scanning Tunnelling Microscope, 
the precursor to the AFM, Gerd Binning and Heinrich Rohrer won the Nobel Prize in 
Physics in 1986. The concept of the AFM is simple: a sharp probe, called a tip attached 
on the end of a flexible beam called a cantilever scans the surface of the sample, driven 
by piezoelectric crystals to raster. In direct contact mode (DC), the tip comes close to the 
sample surface and the cantilever deflects as a function of the total interactions between 
the tip and sample. A laser measures this cantilever deflection and through a feedback 
loop, moves the z-axis of the piezo to keep a constant deflection and therefore force on 
- 26 - 
 
the sample. In the intermittent contact mode, the cantilever is oscillated at it’s resonance 
frequency. As the tip rasters the surface, any interaction between tip and the sample 
results in a change of amplitude of the cantilever oscillation. This change in amplitude is 
registered and the resulting topology is determined.  
Atomic Force Microscopy has a horizontal resolution which is a function of tip 
radius, usually around a few nanometers. Vertical resolution is usually approximately 0.1 
nm. AFM gives only topological information; certain features on the side or under the 
sample are not resolved using the Atomic Force Microscope.   
AFM has been used to image lipids, proteins, inorganic materials, and larger 
structures such as bacteria. In addition to imaging, AFM can be used to measure forces in 
the order of piconewtons. For example, researchers have used the AFM to measure the 
energy required to unfold proteins, separate membranes proteins from lipid membrane, 
and measure the forces required to separate two strands of DNA. 
When the AFM is combined with the Kelvin Method, the instrument is called the 
Kelvin Probe Force Microscope and is used to determining local surface potential 
distribution in non metallic surfaces. 
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Figure 7 - Model of Atomic Force Microscope 
1.4.2. Langmuir-Blodgett Monolayer Technique 
The Langmuir-Blodgett (LB) monolayer technique is used to form a thin film 
composed of surfactant or lipid molecules, which is only  one molecule thick. An LB film 
is formed using a device called the L-B trough. The L-B trough has 2 barriers on either 
side of the trough. A Wilhelmy balance is used to measure the surface pressure of the 
material. The trough is filled with water and a substrate (mica, glass, or silica) is placed 
through the interface. The film material is placed on the air/water interface and the 
material solvent is allowed to evaporate leaving only the film material remaining on the 
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interface. The barriers are then closed to achieve the required surface pressure. Once the 
required surface pressure is reached, the substrate is slowly raised, depositing a 
monomolecular film on the substrate. The substrate may then be lowered and raised again 
to form multilayers. The L-B trough may also be used to obtain surface pressure-area 
isotherm to observe how the surface pressure is affected by trough area. 
 
Figure 8 - Langmuir Blodgett Trough and cartoon of LB deposition 
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Chapter 2 
Effect of Cholesterol and Amyloid-β on Monolayer 
Function 
 
2.1 Description of Experiment 
Cholesterol has been shown to affect the multilayer formation of lipid films and 
Bovine Lung Extract Surfactant (BLES). It has been also shown that the increased 
amount of SP-C leads to amyloidosis and diseased state of surfactant. The goal of our 
research was to determine how both factors affect the surfactant function and 
performance of model lipid monolayers. As SP-C is not readily available, we used 
amyloid-β (1-40) peptide as a substitute for SP-C. We further build on this research to 
determine the affect of the amyloid-β protein on these lipid and BLES films. We mixed 
lipids with cholesterol at 0% and 20% concentrations and with amyloid-β (1-40) at 
concentrations of 0%, 1% and 10%. These mixtures were deposited on the Langmuir-
Blodgett trough. Surface Pressure Area isotherms were collected. L-B trough barriers 
were compressed to their plateau and the lipid material was deposited on mica substrate. 
We used Atomic Force Microscopy to image these films to elucidate the effect of 
cholesterol and amyloid-β on multilayer formation.  
2.2 Materials and Methods 
Sample Preparation 
DPPC (Avanti Polar Lipids) and DPPC with 20% cholesterol by weight were 
dissolved in chloroform at a concentration of 1 mg/mL. Amyloid- β 1-40 (Genscript 
Corporation, Piscataway, USA) was dissolved in DMSO and sonicated for 10 minutes. 
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The DPPC in chloroform solution, was mixed with amyloid-β to obtain solutions with 
1% and 10% amyloid-β by weight.  
DPPC and DOPG (also referred to as eggPG) was mixed weighed and dissolved 
in chloroform at a ratio of DPPC:DOPG 80:20 and a concentration of 10 mg/mL. 
Amyloid-β (1-40) was prepared as noted above and mixed with the DPPC:DOPG 
solution 
Bovine Lung Extract Surfactant (BLES, a kind gift from BLES biochemicals) was 
extracted into chloroform from Goerke's buffer. 0.5 mL BLES in buffer (concentration 27 
mg/mL) was mixed with 0.5 mL methanol and 0.5 mL chloroform and centrifuged for 10 
minutes at 100g. The bottom phase was removed and 0.5 mL chloroform was added to 
the remaining solution. Again the solution (was centrifuged at 100g for 10 minutes and 
the bottom phase was again removed and added to the previous bottom phase. The final 
concentration of the BLES solution was 27 mg/mL. Amyloid-β was prepared as indicated 
above.  
Langmuir-Blodgett Deposition 
A piece of freshly cleaved mica was placed in the arm of the LB trough and 
lowered into the subphase. Approximately 5 µL Protein-lipid solutions were deposited on 
the interface on a Langmuir-Blodgett trough (LB trough) using a 5 µL syringe. Exact 
volume's of solution were adjusted to achieve a surface pressure of 25 mN/m with the 
barriers fully open. The lipid was allowed to spread on the interface for a period of 10 
minutes. The LB trough barriers were compressed at 10 cm2/min to collect surface 
pressure-area isotherms. The mica was raised at a rate of 2 mm/min through the interface. 
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The mica was allowed to air dry for 10 minutes, than affixed on a glass microscope slide 
using double sided tape. 
Imaging 
 The lipid multilayers were imaged in air using a JPK Nanowizard II (JPK 
Instruments, Berlin) Atomic Force Microscope using a 42 N/m Nanoworld cantilever 
with a resonance frequency of  approximately 250 kHz in air in intermittent contact 
mode. 
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2.3 Results 
2.3.1. BLES Multilayer Formation 
 
 Figure 9 - AFM and Kelvin Probe Force Microscopy Image of BLES shows an AFM 
and Kelvin Probe Force Microscopy Image of BLES. We observe discrete multilayer 
formations, of 5 nm in height. In the multilayer in top left of image A, we also observe 
domains within the first monolayer. In the KPFM image on the right, we observe 
multilayer potential below that of the monolayer. However, lighter areas indicate areas of 
higher surface potential. We believe these lighter areas are locations where SP-C is 
present.  
B A 
Figure 9 - AFM and Kelvin Probe Force Microscopy Image of BLES (Hane, et al. 2009) 
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2.3.2. Effect of Cholesterol on BLES and Thin Lipid Films 
 
Figure 10 - Surface Pressure - Area Isotherm of BLES, effect of cholesterol 
 Figure 10 - Surface Pressure - Area Isotherm of BLES, effect of cholesterol shows 
the effect of cholesterol on the surface pressure-area isotherm of BLES with and without 
20% cholesterol. When cholesterol is absent in BLES, surface pressure is allowed to 
increase to 70 mN/m. (The corollary of statement is that surface tension is reduced to 
appoach 0 mN/m, since surface tension is the difference between surface pressure and 
bulk surface tension.) With 20% cholesterol composition, the maximum surface pressure 
of BLES is asymptotic at approximately 48-50 mN/m as trough area decreases. This 
result is in agreement with results obtained by Gunasakara (Gunasekara, et al. 2005)and 
Leonenko (Leonenko, Gill, et al. 2007). 
 
  














































 Figure 11 - BLES without cholesterol shows an AFM image of a BLES 
monolayer compressed to 67 mN/m with no cholesterol. Notice discrete multilayer 
formations of 5 nm in height, corresponding to a lipid bilayer or multiples of them. 
Multilayers are numerous and well distributed. Cross section shows a height of the 
second multilayer of 10 nm. 
 
Figure 11 - BLES without cholesterol 




















 Figure 12 - BLES with 20% cholesterol shows an AFM image of a BLES 
monolayer compressed to 25 mN/m. There is an absence of defined multilayer 
formations. Notice cross section of few lipid protrusions. Surface is uneven and 
continuous in height. 
 
 
Figure 12 - BLES with 20% cholesterol 


















 Figure 13 - DPPC-DOPG composition, no cholesterol shows an AFM image of a 
DPPC-DOPG monolayer compressed to 59 mN/m with no cholesterol. Similar to BLES, 
model lipid mixture forms discrete multilayer formations of 5 nm in height, 
corresponding to a lipid bilayer. Multilayers are numerous and well distributed. Cross 




Figure 13 - DPPC-DOPG composition, no cholesterol 




















 Figure 14 - DPPC-DOPG composition with 20% cholesterol shows an AFM 
image of a DPPC-DOPG (80:20 ratio) monolayer compressed to 55 mN/m. We observed 
unusual rod-like single bilayer formations with a height of 5 nm when the monolayer was 
compressed. The length of these rods varied from 1-5 µm in length and a consistent width 
of 0.5 µm. 
Figure 14 - DPPC-DOPG composition with 20% cholesterol 





Figure 15 - DPPC with no cholesterol 
 Figure 15 - DPPC with no cholesterol shows an AFM image of a DPPC 
monolayer compressed to 40 mN/m, with no cholesterol. We observed numerous, well 
distributed, amorphous multilayer formations. Cross section shows discrete multilayers of 
height 5, 25, 30 and 10nm. 


















 Figure 16 - DPPC with 20% cholesterol shows an AFM image of a DPPC 
monolayer with 20% cholesterol compressed to 50 mN/m. We observed an absence of 
typical discrete lipid multilayer formations. We observe small patches of lipid material 
with heights to 50 nm. These may be multilayers, but the are much smaller and less 
discrete than multilayer patches found in DPPC without cholesterol. In summary: 
cholesterol in BLES and model lipid films suppresses multilayer formation observed by 
AFM, and does not allow it to achieve higher compressions in the Langmuir isotherms.  
  
Figure 16 - DPPC with 20% cholesterol 
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2.3.3. Effect of Amyloid-Β on BLES and Thin Lipid Films 
 
Figure 17 - Surface Pressure-Area Isotherms of BLES with differing concentrations of Amyloid-β 
 Figure 17 - Surface Pressure-Area Isotherms of BLES with differing 
concentrations of Amyloid-β shows the surface pressure-area isotherms of BLES with 
varying concentrations of amyloid-β. Notice that without the presence of amyloid-β, the 
surface pressure of BLES reaches around 70 mN/m (corresponding to a surface tension of 
0 mN/m). Once amyloid-β is added in either 1% or 10% concentrations, the maximum 
surface pressure is reduced to approximately 45 mN/m. 
  

















































 Figure 18 - BLES with 1% Amyloid-Β shows an AFM image of BLES monolayer 
with 1% amyloid-β compressed to 48 mN/m. While amorphous patches may resemble 
multilayer patches, note the difference in height. The bright white patches have a height 
of 10 nm, which falls within discrete 5nm steps. However, the image shows the height of 
the lower patches of lipid to be only 2nm in height, which does not correspond to a 5 nm 
high bilayer. 
Figure 18 - BLES with 1% Amyloid-Β 




















 Figure 19 - BLES with 10% Amyloid-Β shows an AFM image of BLES 
monolayer with 1% amyloid-β compressed to 47 mN/m. We observe small, thread like 
formations with a height varying from 20 nm continuously to 100 nm. These formations 
are likely protein or protein-lipid mixtures, being “squeezed-out” of the monolayer at 
higher compressions. 
Figure 19 - BLES with 10% Amyloid-Β 
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Figure 20 - Surface Pressure-Area Isotherms of DPPC-DOPG with different concentrations of Amyloid-β 
  Figure 20 - Surface Pressure-Area Isotherms of DPPC-DOPG with different 
concentrations of Amyloid-β shows a surface pressure-area isotherm of a lipid 
composition of DPPC-DOPG at a 80:20 ratio. Without any peptide, the maximum surface 
pressure achieved by the composition is 48 mN/m. Once 1% or 10% amyloid-β is added 



















































 Figure 21 - DPPC-DOPG composition 1% Amyloid-β shows an AFM image of 
BLES monolayer with 1% amyloid-β compressed to 69 mN/m. We observe large, 




Figure 21 - DPPC-DOPG composition 1% Amyloid-β 



















 Figure 22 - DPPC-DOPG composition 10% Amyloid-β shows an AFM image of 
BLES monolayer with 10% amyloid-β compressed to 70 mN/m. We observe numerous, 
well distributed, multilayer formations of variable shapes. Discrete bilayers are 5, 10, 15, 




Figure 22 - DPPC-DOPG composition 10% Amyloid-β 
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Figure 23 - Surface Pressure-Area Isotherms of DPPC with different concentrations of Amyloid-β 
 Figure 23 - Surface Pressure-Area Isotherms of DPPC with different 
concentrations of Amyloid-β is a surface pressure-area isotherm of DPPC with varying 
concentrations of amyloid-β added. Absent amyloid-β, the maximum surface pressure of 
DPPC is 55 mN/m. Once 1% and 10% of amyloid-β is added to the DPPC, the maximum 



























































Figure 24 - DPPC 1% Amyloid-β shows an AFM image of a DPPC monolayer 
with 1% amyloid-β compressed to 65 mN/m. We observe numerous, well distributed, 




Figure 24 - DPPC 1% Amyloid-β 



















 Figure 25 - DPPC 10% Amyloid-β shows an AFM image of a DPPC monolayer 
with 10% amyloid-β compressed to 70 mN/m. We observe numerous, amorphous limpid 





Figure 25 - DPPC 10% Amyloid-β 
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 Figure 26 - BLES with 20% cholesterol and 1% Amyloid-βshows an AFM image 
of a BLES monolayer with 20% cholesterol and 1% amyloid-β compressed to 48 mN/m, 
which is a maximum compression possible in the presence of cholesterol. We observe no 
perceptible multilayer formations, but only small, infrequent patches of lipid material 
varying continuously between 0 and 35 nm. This is not indicative of any multilayer 
formation, but rather non-structured aggregates.  
Figure 26 - BLES with 20% cholesterol and 1% Amyloid-β 













 Figure 27 - BLES with 20% cholesterol and 10% Amyloid-β shows an AFM 
image of a BLES monolayer with 20% cholesterol and 1% amyloid-β compressed to 48 
mN/m. We do observe flat multilayer formations, and at the same time amorphous 
clusters on the top of the multilayers. 
  
Figure 27 - BLES with 20% cholesterol and 10% Amyloid-β 















 Figure 28 - DPPC-DOPG composition with 20% cholesterol and 1% Amyloid-β 
shows an AFM image of a DPPC  monolayer with 20% cholesterol and 1% amyloid-β 
compressed to 47 mN/m. We observe, long, whispy structures terminating with large 
circular aggregates approaching 200 nm in height. The composition of the long, curly 
structures is unknown, the larger aggregates are most likely composed of peptide or 
peptide-lipid aggregates.  
Figure 28 - DPPC-DOPG composition with 20% cholesterol and 1% Amyloid-β 




















Figure 29 - DPPC-DOPG composition with 20% cholesterol and 10% Amyloid-β 
shows an AFM image of a DPPC  monolayer with 20% cholesterol and 1% amyloid-β 
compressed to 50 mN/m. We observe small round clusters, of what we believe, are 
composed of a protein-lipid mixture. Maximum height of the smaller clusters is 5-10 nm, 
while larger clusters are upwards of 30 nm high. Boundaries of these clusters are 
continuous which is unlike the discrete multilayers observed in BLES or DPPC-DOPG 
lipid films.  
Figure 29 - DPPC-DOPG composition with 20% cholesterol and 10% Amyloid-β 
- 53 - 
 














 Figure 30 shows a BLES monolayer with 10% amyloid-β compressed to 25 
mN/m. We observe round liquid condensed-liquid expanded domains with a height 
difference of 0.2-0.4 nm. Observing the  larger liquid expanded domains, we can see they 
are made up of smaller domains, that have been fused together forming larger domains. 
At the phase interface, we observe aggregations of peptide. 
Figure 30 - BLES monolayer with 1% Amyloid-β compressed to 25 mN/m 















 Figure 31 - BLES monolayer with 1% Amyloid-β compressed to 50 mN/m shows 
a BLES monolayer with 10% amyloid-β compressed to 50 mN/m. We observe long 
microtubular aggregates connected to each other. The height of this clusters varies 
continuously, but approaches 40 nm in some areas. They are not flat as the multilayers 
we observed earlier without peptide. Most likely these clusters are peptide-lipid 
aggregates, which might be forced out of the monolayer at higher compressions. If we 
Figure 31 - BLES monolayer with 1% Amyloid-β compressed to 50 mN/m 
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look closely at the monolayer, we observe very small liquid expanded domains. These 
domains are less visible because of the z-scale required to accurately asses the peptide 
aggregates. 
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2.4 Discussion 
2.4.1. Effect of cholesterol on thin lipid films 
We found that for all investigated films, BLES, pure DPPC, or mixed DPPC-
DOPG, high concentrations of cholesterol impairs surface tension reducing properties, 
which are required for proper function of pulmonary surfactant. In surface pressure-area 
isotherms (Figure 10), we notice a remarkable plateau at around 48 mN/m, with no 
further increase in surface pressure. This is a result of the cholesterol inhibiting 
multilayer formation causing excess material to drop into the liquid subphase as opposed 
to forming multilayers. Figure 11 shows a typical BLES multilayer formation. 
Gunasekara (Gunasekara, et al. 2005) and Leonenko (Leonenko, Gill, et al. 2007) showed 
that the addition of cholesterol to BLES resulted in the abolishment of surface activity of 
BLES. Our data is in good agreement with data reported earlier by these authors on 
BLES and extend these to the DPPC-DOPG mixture. Keating (Keating, et al. 2007) 
showed that mice ventilated with BLES and cholesterol showed lower arterial oxygen 
concentrations. Our of DPPC with cholesterol is in good agreement with Hoon, et. al 
(Hoon, Takizawa and Urisu n.d.). 
2.4.2. Effect of Low Concentrations (1%) of Amyloid-Β on BLES and DPPC, 
DPPC-DOPG lipid films 
Addition of low concentrations of amyloid-β peptide showed an improvement in 
multilayer formation in both DPPC and DPPC-DOPG films. Isotherms showed a 
significant increase in maximum surface pressure upon the addition of 1% amyloid-β. It 
has been shown earlier that these features are interconnected with each other in BLES 
films, and thus successful formation of multilayer structures is associated with proper 
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functioning of BLES surfactant. Examination of topographical AFM images shows that 
multilayer surface coverage increased in both DPPC and DPPC-DOPG mixtures upon the 
addition of 1% amyloid-β. As well, higher multilayers tended to form in DPPC-DOPG 
mixtures, similar to BLES films. Therefore we illustrated here that small amount of 
amyloid-β peptide in model lipid films can serve the same purpose as SP-C protein in 
BLES, and can improve multilayer formation and therefore the function of the DPPC, or 
DPPC-DOPG mixed film, as a simple model of pulmonary surfactant. Previous research 
by Dante (Dante, Hauss and Dencher 2003) showed using neutron diffraction that 
amyloid-β incorporates deeply into POPC lipid films and perturbs the lipid bilayer. Our 
data obtained here are consistent with this finding. According to the proposed model 
(Leonenko, Gill, et al. 2007) (Amrein, von Nahmen and Sieber 1997), we believe that it 
is possible that the alpha-helical section of the amyloid-β peptide incorporates into the 
lipid bilayer, the random coil section may act as an anchor, allowing the peptide to 
become a molecular hinge, similar in function to SP-C. 
Next, 1% of amyloid-β was incorporated into the BLES. Surface coverage of 
BLES multilayers with peptide present remained similar (Figure 18) to BLES without 
peptide added (Figure 11). Isotherm data showed a decrease in maximum surface 
pressure from 70 mN/m to around 50 mN/m (Figure 17).  
The addition of 1% amyloid-β to DPPC (Figure 24) and DPPC:DOPG (results not 
shown) result in an increase of maximum surface pressure from around 48 mN/m to 
around 70 mN/m once peptide is added (Figure 23). Existing literature indicates that both 
DPPC and DOPG should reach surface pressures approaching 70 mN/m, however on our 
trough, we were unable to achieve surface pressure of greater than 55 mN/m.  We were 
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able to achieve higher surface pressures with 1% amyloid-β added. While quantitative 
analysis was difficult, we can qualitatively say that amyloid-β added to thin lipid films 
improves surface activity of the film. This leads us to believe that, amyloid-β allows the 
film to achieve higher surface pressures more readily with less compression. The 
interesting result from this experiment is the counterintuitive result that surface pressure 
area isotherms of BLES (Figure 17) showed a decrease in maximum surface pressure 
with the addition of low concentrations of amyloid-β from 70 mN/m without peptide to 
around 48 mN/m with the peptide added. This means that the ability of lipid films to 
reduce surface tension is improved upon the incorporation of small amounts of amyloid 
β, while it is reduced for BLES. This could be due to the fact that SP-C at concentration 
of approximately 0.5%-1%, which is similar to amyloid-β, is already present in BLES 
mixture, and therefore additional increase in the total amount of peptide is not favourable.  
2.4.3. Effect of High Concentrations (10%) of Amyloid-Β on BLES and DPPC, 
DPPC-DOPG lipid films 
As with low concentrations of amyloid-β, high concentrations of amyloid β 
showed a higher maximum surface pressure plateau in both DPPC and DPPC-DOPG 
mixtures of approximately 70 mN/m (Figure 25 and Figure 22). High concentrations of 
amyloid-β in DPPC and DPPC-DOPG showed multilayer formation surface coverage and 
height to be similar to low concentration compositions, however the morphology of the 
multilayers was occasionally different. Multilayers in 10% amyloid mixtures tended to be 
more circular in shape, whereas 1% amyloid mixtures yielded multilayers which tended 
to have various shapes and sizes (Figure 24, Figure 21).  
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 Addition of 10% amyloid-β to BLES showed a decrease in maximum surface 
pressure plateau at 48 mN/m, compared to a maximum surface pressure of 70 mN/m in 
BLES without any peptide added (Figure 17). This phenomenon leads us to conclude that 
the addition of high concentrations of amyloid-β makes it unfavourable for the peptide to 
be incorporated into the lipid monolayer. At higher compressions (47 mN/m), AFM 
images showed no multilayer formation, but unique patterns of peptide aggregates.  Little 
multilayer formation was observed, as compared to BLES without any peptide added. 
These aggregates reached heights of up to 50 nm.  
2.4.4. Effect of Cholesterol and Amyloid-β on BLES and DPPC, DPPC-DOPG lipid 
films 
Since BLES contains numerous proteins whose function is to improve surfactant 
function, and cholesterol inhibits surfactant function in BLES, it can be predicted that 
cholesterol would also inhibit multilayer formation in lipids with alpha-helical peptides 
added. BLES, DPPC and DPPC-DOPG all showed no multilayer formation and lower (48 
mN/m) surface pressure area isotherm plateau's when cholesterol and 1% amyloid-β were 
added to the lipid mixture (isotherm not shown). Research by Ji concluded that (Ji 2002) 
there is a stronger interaction between amyloid-β and cholesterol than between amyloid-β 
and lipids.  This would explain our results of difficulties in incorporation of peptide into 
monolayers rich in cholesterol. 
However, when we added 10% amyloid-β to BLES, we saw a return of multilayer 
formation suggesting that at high concentrations, (Figure 27) amyloid-β may counteract 
the destructive effect of cholesterol return some surfactant function to BLES. 
2.4.5. Effect of Compression on BLES multilayer formation  
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Our data showing the aggregation of peptide on the gel/fluid phase boundary at 
low compressions (Figure 30) correlate well with the data shown by Choucair (Choucair, 
et al. 2007) who showed preferential binding of amyloid fibrils on gel phase domains on 
the lipid membrane. Ege (Ege and Lee 2004) allowed peptide to bind to the monolayer 
from the subphase observed using fluorescence microscopy  that the phase boundary 
became “fuzzy”, suggesting that these are the preferred locations for the peptide. As 
surface pressure is increased, the remainder of the lipid materials is compressed into gel 
phase and domain boundary disappears (Figure 31). At this point, the unincorporated 
peptide is left to reside at the surface of the monolayer rather than incorporating. By 
comparing figures Figure 30 and Figure 31, we notice, what appears to be more peptide in 
the sample with higher compression (Figure 31). Ege also showed that the level of 
peptide insertion is inversely proportional to the packing density of the lipids (Ege and 
Lee 2004). We believe that in BLES, this occurs because peptide is being “squeezed out” 
or “unincorporated” out of the monolayer and is either dropped into the subphase or 
pushed to the air surface. This should be fairly obvious conclusion: as surface pressures 
increase, the peptide cannot insert as easily into the lipid monolayer.  
Maltseva used a combination of grazing incidence x-ray diffraction and internal 
reflection absorption spectroscopy to study the interaction of lipid monolayers and 
amyloid-β (Maltseva, et al. 2005). The results Maltseva obtained show that at surface 
pressures higher than 30 mN/m, the peptide was squeezed out of the lipid monolayer. 
These data are consistant with our results. 
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Chapter 3 
Binding of Amyloid-β to Lipid Membranes 
 
3.1 Description of Experiment 
The amyloidosis process varies depending on the environment of amyloid-β. In 
solution, amyloid-β forms fibrils which increase in length and width as a function of 
time. We believe that the interaction of amyloid forming peptide is important for the 
mechanism of amyloid formation, especially at the initial stages. Amyloid-β allowed to 
incubate on lipid membranes will not yield the same results as amyloid-β which is left to 
aggregate in aqueous solution without the presence of lipid membranes. In this 
experiment, we deposited amyloid-β on lipid bilayers of DPPC (zwitterionic), DOPG 
(anionic) and DOTAP (cationic) and allowed the peptide to incubate for various periods 
of time. At the end of incubation, we imaged supported bilayers in water using atomic 
force microscopy to observe any possible fibril or oligomeric formation in or on the lipid 
bilayer. 
3.2 Materials and Methods 
Lipid Bilayer Preparation 
DPPC, DOPG and DOTAP lipids were purchased from Avanti Polar Lipids 
(Alabaster AL). Lipid vesicle solution was prepared by adding 0.5 mg of lipid in 1 mL of 
ultrapure water. The lipid solution was stirred for 15 minutes, followed by 10 minutes of 
ultrasonic sonication. This stirring/sonication procedure was repeated until the lipid 
solution was clear. This indicated that lipid vesicles had formed. 100µL of vesicle 
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solution was placed on freshly cleaved mica. Vesicles were allowed to fuse for 15 
minutes. The sample was washed with ultrapure water to remove unfused vesicles. 
DOTAP bilayers do not easily bind to mica sheets. Therefore, an additional step was 
taken with DOTAP bilayers: mica sheets were chemically modified with APTES 
solution, by irrigating mica in APTES for 10 minutes and rinsing it with ultrapure water. 
Samples of each lipid bilayer (DPPC, DOPG and DOTAP) were imaged with the atomic 
force microscope to ensure uniformity of the bilayer. One sample of each lipid was rinsed 
vigourously with ultrapure water, causing “nanoholes” in the lipid bilayer. When imaged, 
these samples with holes allow us to measure the depth of the holes indicating the 
thickness of the lipid bilayer. We measured a hole depth of 5nm indicating a correct 
bilayer height of 5nm.  
Amyloid-β Incubation 
Amyloid-β (1-42) was purchased from rPeptide Inc. (Bogart, GA).  rPeptide has 
prepared the peptide in an NaCl counter ion in accordance with the Fezoui procedure 
(Fezoui, et al. 2000). 1 mL of HEPES buffer (50 mmol, pH 7.8) was added to a 0.5mg 
vial of amyloid-β peptide. The solution was sonicated for 1 minute as directed by 
rPeptide literature. 100µL amyloid-β of peptide solution was placed on the lipid bilayers 
and was incubated at room temperature for the defined time periods of 10 minutes, 1 
hours, 6 hours, and 24 hours. At the conclusion of incubation time, unbound peptide was 
gently rinsed with 50µL of ultrapure water three times as described in (Choucair, et al. 
2007). Nanopure water was added in sufficient quantity to cover the mica slide during 
imaging with the atomic force microscope. 
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For control experiments, 100µL amyloid-β was placed on mica and allowed to 
adsorb for 5 minutes. Excess peptide was rinsed with 50µL three times. 
Atomic Force Microscopy Imaging 
Samples were placed in the liquid cells provided by JPK Instruments AG. The 
liquid cells were filled with nanopure water, covering the entire sample. The liquid cells 
were placed in the atomic force microscope. All samples were imaged in liquid. To 
collect images using the JPK Nanowizard II instrument, we used a Veeco DNP-S 
cantilever designed for liquid cell use. Calibration (laser alignment and tuning) was 
completed in accordance with the JPK user manual. Images were scanned at a line rate of 
0.5Hz and a set point between 0.18-0.30V. 
Analysis 
Images were processed with JPK image processing software. Images were 
levelled by subtracting a polynomial fit from the images, and some images were adjusted 
by adjusting the MinMax z-range to emphasize desired features. For example, if certain 
features have a variation of height between 2 and 10 nm, but we are only concerned that 
these features are present, but want to observe the underlying lipid topology as well, we 
adjusted the z-range to display these features as the same colour (mostly white), while 
having a contrast for lipid topology differences. In each case, cross sections were taken to 
show representative height. A few images have been altered by the application of a low 
pass filter and the replacement of certain pixels by using the mean of neighbouring 
pixels. These filters were added to improve image quality. 
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Quantitative analysis of number of oligomers and oligomer surface area was 
conducted with ImageJ software. The colour AFM image converted to an 8-bit image and 
the threshold was adjusted to include all higher objects (oligomers and fibrils) and omit 
the background (bilayer). Particles were than analyzed and the software calculated 
various statistical values for the number of oligomers, mean particle area, and min and 
max area.  
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3.3 Results 
3.3.1. Amyloid-β Incubated in Solution (Control) 
 
Figure 32 - Amyloid-β incubated in solution 1 hr 
 In Figure 32 we observe the result of amyloid-β incubated for 1 hr in solution and 
placed on mica. After 1 hr of incubation, we observe that small amyloid-β oligomers start 
to form. These oligomers are all circular in shape with a height of between 1 and 3nm.  




Figure 33 - Amyloid-β incubated in solution 24hr 
 Figure 33  shows amyloid-β which has been allowed to incubate in solution for 24 
hrs. We observe extensive long, thick fibrils, having a length of up to 5 µm and a height 
of between 2 and 6 nm. Also, we see small spherical aggregates which most likely are 
oligomers of peptide which have not yet aggregated into fully mature fibril form.  
 




Figure 34 - Amyloid-β incubated on DPPC bilayer 1hr 
 Figure 34  show amyloid-β incubated on a DPPC bilayer for a period of 1 hr. We 
observe formation of oligomeric structures of up to 3nm high with a width of between 
100-500 nm. Both small and larger oligomers are present and have a mean area of 0.066 
µm2. 
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Figure 35 - Amyloid-β incubated on DPPC bilayer 24hr 
 Figure 35 shows amyloid-β incubated on DPPC for 24 hours. We observe small 
prolongated oligomers connected to each other, that completely cover the surface of mica 
and are approximately 0.5-22 nm high and 0.1 µm in length.  
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Figure 36 - Amyloid-β incubated on DPPC bilayer 24hr 
 Figure 36 shows a small scale image of amyloid-β incubated on DPPC bilayers 
for 24 hours. On close examination, we see very small fibril structures with a height of 
0.25nm (see left side of cross section). Larger oligomeric structures approach 1.5nm in 
height.   




Figure 37 - Amyloid-β incubated on DOPG bilayer 1hr 
 Figure 37 shows amyloid-β incubated for 1 hour on a DOPG bilayer. We observe 
numerous, small spherical oligomers with a height of 1-3nm. Oligomers are well 
distributed. On close examination, we observe some of these oligomers have formed very 
small fibrils with a height of approximately 0.2nm. They appear spherical and separated 
from each other, unlike clusters we observed earlier on DPPC bilayer. 
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Figure 38 - Amyloid-β incubated on DOPG bilayer 1hr 
 Figure 38 shows a high resolution image of amyloid-β incubated on a DOPG 
bilayer for 1 hour. We observe frequent, round oligomers with a height of between 1 and 
3 nm. Very small fibrils appear to form in areas outside of the oligomers with a width 
approaching the lateral resolution of the image. The height appears to be approximately 
0.2nm (see left side of cross section). 
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Figure 39 - Amyloid-β incubated on DOPG bilayer 24hr 
 Figure 39 shows amyloid-β incubated on a DOPG bilayer for 24 hours. We 
observe numerous elongated oligomers with a height of 3 nm. Occasional small fibril-like 
structures are seen in the background. 
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Figure 40 - Amyloid-β incubated on DOPG bilayer 24hr 
 Figure 40 is a high resolution image of amyloid-β incubated on a DOPG bilayer 
for 24 hours. We observe few fibril structures with a height of 0.5nm. Fibrils appear to be 
straight and no longer than 100µm in length. On close examination, 3 fibrils located in 
the upper left quadrant of Figure 40 appear to have some twist to them. 
 





Figure 41 - Amyloid-β incubated on DOTAP bilayer 10min 
 Figure 41 shows amyloid-β incubated on a DOTAP bilayer for 10 minutes. We 
observe oligomers with a height of 1nm and mean area of 0.053µm2. We observe no 
individual fibrils, but rather interconnected, poorly-defined in structure aggregates.
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Figure 42 - Amyloid-β incubated on DOTAP bilayer 24hr 
 Figure 42 shows amyloid-β incubated on a DOTAP bilayer for 24 hours. We 
observe large round, flat, patch-likeclusters of material reaching up to 80 nm high. Lower 
clusters reach 20 nm high. We are uncertain whether these clusters are composed of 
lipids, proteins, or a combination of the two. The top part of the image shows what 
appear to be small fibrils. These are difficult to resolve because of the large z-range of the 
image caused by the larger clusters. 
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Figure 43 - Amyloid-β incubated on DOTAP bilayer 24hr 
 Figure 43 shows a high resolution image of amyloid-β incubated on DOTAP 
bilayers for 24 hours. We observe no single amyloid oligomers but rather entangled 
plaque-like structures, such as one with a height of 3.5 nm and width of 200 nm, shown 
on Figure 43 - Amyloid-β incubated on DOTAP bilayer 24hr, cross-section. 
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3.4 Discussion 
Amyloid-β, when cleaved from its precursor protein, is implicated in the 
neurotoxicological symptoms manifesting as Alzheimer’s disease as a result of the 
misfolding of this peptide. How this protein interacts with lipid cell membranes is 
essential to understanding the mechanism of action of amyloid-β. Given that extensive 
work has been done on the misfolding and aggregation of amyloid-β in solution, we 
compared this aggregation to the aggregation of amyloid-β and growth of amyloid fibrils 
incubated on lipid bilayers DPPC (neutral), DOPG (anionic) and DOTAP (cationic). 
While cationic lipids are not present in cell membranes (Ege and Lee 2004), it was 
important to compare the interactions of amyloid-β between lipids of different charges to 
better understand the electrostatic interactions between amyloid-β and lipid membranes. 
We allowed amyloid-β to incubate on lipid bilayers and then used the atomic force 
microscope to study how amyloid-β interacts with cell membranes. AFM images were 
compared both qualitatively and quantitatively using ImageJ software to count aggregates 
and determine their mean size. 
The difference in fibril formation between amyloid-β incubated in solution and 
amyloid-β incubated on lipid bilayers is striking: in solution, we observe extensive fibril 
formation in which fibrils grow in both length and width with increasing time. For 
example, area distribution analysis conducted comparing Figure 32 and Figure 33 
indicate that while the number of oligomers or fibrils stays constant, the size of the fibrils 
is radically increased. Figure 32 shows amyloid peptides which have been incubated in 
solution for 1 hour. A total of 301 oligomers are seen in the image with an average 
oligomer size of 0.029 µm2.  Figure 33 shows the amyloid peptide after being incubated 
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for 24 hours in solution. However, while we observe an almost equal number of 
oligomers: 283, the peptide has aggregated to form large fibrils and oligomers, which 
average 0.5 µm2 in area. However, when we allow amyloid-β to incubate on lipid 
bilayers, we do not see the large fibrils associated with solution incubation. Importantly, 
both fibrils and spherical oligomers are well resolved when are formed in solution or on 
supported surfaces (mica). When fibrils are formed on supported lipid bilayers, the 
structure of fibrils or oligomers are not well resolved, have lower height and seem to fuse 
with the bilayer. This effect is larger for DOTAP, than DOPG, and smaller on DPPC. 
This observation suggests that at the initial stage of amyloidosis, small oligomers or even 
monomers interact strongly with the lipid bilayer. We hypothesize that lipids have a 
lower packing density when in the fluid phase, compared to lipids the gel phase, therefore 
peptides insert more readily in fluid phase bilayers than in gel phase bilayers (Ege and 
Lee 2004). Our results are consistant with this hypothesis: peptide aggregates have larger 
height and are better resolved on the surface of gel phase DPPC bilayer, than on the 
surface of fluid phase DOPG and DOTAP bilayers.  
Amongst the different lipids, we see differences in their interactions with 
amyloid-β. In DPPC, we see an increase in both the number of oligomers and the mean 
size of the oligomers as incubation time increases. We observe the following increase in 
the number of oligomers (for 10 min, 1hr, 6hr, 24hr respectively): 95, 117, 343, 773. The 
mean size of the oligomers also increases, ranging from 0.053 µm2 for a 10 minute 
sample to 0.084µm2 at the 6 hour sample. However, by the time 24 hour sample, the 
mean peptide area is reduced to 0.054µm2. This decrease is likely due to   amyloid-β 
peptide forming thin fibrils which have much smaller area as compared to oligomers.  
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In DOPG, we see a constant number of oligomers (approximately 300) and 
average size regardless of incubation time. The mean peptide area is between 0.055µm2 
and 0.067µm2. However, Figure 39 demonstrates that approaching a time of 24 hours, 
amyloid-β incubated in DOPG forms small fibrils which would not be reflected in simply 
measuring mean oligomer area.  
The fibrils-like structures seen in DPPC and DOPG bilayers appear to be 
significantly smaller, than those seen deposited on mica after solution incubation. Fibrils 
incubated on DPPC and DOPG bilayers have a height of approximately 0.2nm, which 
approaches the z-range resolution limit of the AFM. This suggests that these small fibrils 
have embedded themselves into the lipid bilayer, and only a small top portion is showing. 
While we believe these structures to be fibrils, it is difficult on this small of a scale to 
definitely say that these fibril-like structures are in fact amyloid fibrils. Further research 
using fluorescence may provide a definitive answer. 
DOTAP showed mean oligomer area and number of oligomers consistent with 
DPPC and DOPG bilayers. After 10 minutes of incubation, Figure 41 shows 178 
oligomers with a mean area of 0.0528 µm2.  Figure 42 shows peptide incubated on 
DOTAP for 24hr. We observe a significant disruption of the lipid bilayer indicating a 
strong interaction between the peptide and the lipid bilayer. This excess material (perhaps 
DOTAP or DOTAP protein mixtures) reaches a height of up to 60nm. We believe this 
phenomenon is a result the DOTAP bilayer interacting strongly with the peptides, 
forming peptide-lipid aggregates. Because of this significant membrane disruption in 
24hr samples, quantitative analysis of the number of oligomers was difficult.   At high 
resolution, we were able to observe amyloid oligomers fused with the surface of a 
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DOTAP bilayer. Figure 43 shows a high resolution image of an amyloid-β oligomer in a 
DOTAP bilayer incubated for 24 hours. We observe clusters 3nm high allowing us to 
conclude that there strong interaction of amyloid peptides with the lipids in DOTAP 
bilayers. We observe that the number of oligomers found in the cationic DOTAP bilayer 
after 10 minutes, 178, is significantly less than the number of oligomers found in DOPG 
at a comparable time of 1 hour, 543, but considerably more than the 95 oligomers 
observed on DPPC.  
We believe that when amyloid-β comes in contact with lipids, there is an 
electrostatic interaction between the peptide and lipid. As the charge of the lipid diverges 
from neutral, we believe that the electrostatic interaction between lipid and peptide 
increases and may alter the kinetics of conformational change of amyloid-β. From our 
data, we believe that the stronger the charge difference between peptide and lipid, the 
greater the peptide adsorption to the lipid membrane. We base this theory on a couple 
observations: firstly, the number of oligomers found in anionic DOPG seems to remain 
constant as incubation time increases. This indicates that amyloid-β adsorbs unto it’s a 
DOPG bilayer almost immediately. However, the adsorbed oligomer count of neutral 
DPPC increased with increasing incubation time suggesting that as amyloid-β is 
incubating on the lipid bilayer, it is adsorbed into the bilayer, but does not disrupt the 
bilayer. Cationic DOTAP was more similar to anionic DOPG: within 10 minutes, a 
significant number of oligomers were already found embedded onto the cationic bilayer. 
After 24hr, we notice a significant disruption of the lipid bilayer. Secondly, we observe 
that peptides incubated on lipid bilayers misfold differently than peptide in solution. In 
solution, we find only a hydrophobic effect, where we would expect an α-helix-β-sheet 
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equilibrium to favour the β-sheet conformation. When allowed to incubate on charged 
lipid bilayers, the peptide experience both electrostatic interactions as well as the 
hydrophobic effect, driving the peptide into the lipid bilayer. On neutral DPPC, we only 
have a hydrophobic effect driving the peptide onto the bilayer and no electrostatic 
interaction. Research by a number of labs have shown that amyloid-β binds preferentially 
to anionic lipids (Terzi, Holtzmann and Seelig, Self Association of Amyloid beta in 
solution and binding to lipid membranes 1995) ds. This increase in affinity to anionic 
DOPG has been attributed to an electrostatic interaction between the amyloid-β peptide 
and the lipid headgroups (Bokvist, et al. 2004) (Maltseva, et al. 2005) (Ege and Lee 
2004) (Ji 2002). Our results, as well as results by Ege show that amyloid-β can bind to 
cationic lipids just as readily as anionic lipids (Ege and Lee 2004). For our experiments, 
we dissolved the peptide in HEPES buffer solution at a pH of 7.8, whereas the isoelectric 
point of amyloid-β  is 5.5 (Fezoui, et al. 2000). While the overall net charge of the 
peptide is negative at relevant pH, the peptide still has local positive and negative charges 
based on the primary amino acid sequence. Bockvist has theorized that amyloid-β has a 
local positive charge around Lys28 (Bokvist, et al. 2004). Bockvist showed that when this 
positively charged part of amyloid-β, comes into contact with anionic DOPG, the 
amyloid-β is attracted to the negatively charged headgroups on both sides of the bilayer 
(Bokvist, et al. 2004). This electrostatic effect forces the peptide deep into the bilayer. 
However, the electrostatic interaction in zwitterionic DPPC is not nearly as strong. 
Therefore, we see a considerably lower number of oligomers found in the DPPC bilayer. 
With an increase in incubation time however, the amyloid-β peptide is slowly 
incorporated into the DPPC bilayer resulting in the increase in oligomers in the lipid 
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bilayer. At room temperature, DPPC is in a gel phase, whereas DOPG is in a fluid phase. 
Amyloid-β incorporates into bilayers with lower surface pressures more readily than 
those with higher surface pressures leading us towards the idea that amyloid-β would 
incorporate into fluid phase (DOPG and DOTAP) bilayers more readily than DPPC 
bilayers.  
Choucair (Choucair, et al. 2007) used a combination of AFM and Total Internal 
Reflectance Microscopy (TIRF) to study the effect of amyloid-β insertion on neutral 
DPPC:DOPC bilayers. Choucair indicates no evidence of amyloid-β insertion into the 
lipid bilayer, which is also consistent with the theory that because of electrostatic 
interactions, amyloid-β has difficulty inserting into neutral bilayers. 
Using a combination of FTIR and AFM, Sharpe and Forrest showed that insulin 
had unfolding kinetics highest when adsorbed on cationic lipids, followed by anionic 
lipids, than followed by bulk solution (Sharpe 2002).Sharpe suggests an explanation for 
this phenomenon as a thermodynamic interplay of entropic and enthalpic process that 
direct misfolding kinetics when the peptide is adsorbed to the lipid.  
Bockvist has suggested that once incorporated into lipids, amyloid-β is stabilized 
and prevented from aggregating, inhibiting fibril formation (Bokvist, et al. 2004). This 
suggestion is consistent with our observation of considerably smaller fibrils. However, it 
has been shown that the actual oligomers are more toxic than the fibrils, leading us to 
suggest that this stabilization of amyloid-β in the cell membrane may not actually be 
beneficial from a neurotoxicological perspective. 
Further research into these lipid-amyloid-β interactions should be conducted by 
allowing amyloid-β to be incubated on solution and allowed to adsorb on various lipid 
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membranes and imaged. This would allow us to observe with the AFM the two different 
methods of amyloid-β binding to lipid membranes as Bockvist has suggested (Bokvist, et 
al. 2004). 
  





4.1 Overview of Results 
In our first experiment, we have demonstrated the effect of amyloid-β and 
cholesterol on lipid films of DPPC, DPPC-DOPG and BLES. We saw that cholesterol 
inhibits multilayer formation in all monolayers. Amyloid-β increases multilayer 
formation in DPPC and DPPC-DOPG, but reduced multilayer formation in BLES. When 
cholesterol and amyloid-β is added to BLES, 1% amyloid-β has no observable effect, 
whereas 10% amyloid-β allows BLES to regain some of its surfactant function. Therefore 
we conclude that amyloid-β alters surface activity of the surfactant BLES and model lipid 
monolayers, and at lower concentrations helps to counteract the destructive effect of high 
concentrations of cholesterol. 
In our second experiment, we showed that fibril formation of amyloid-β is 
different on the surfaces of lipid bilayers when compared to fibril formation in solution 
(protein only interaction).  Much larger fibrils are formed in solution compared to what is 
formed on lipid bilayers. Also, the lipids themselves interact with peptide monomers and 
oligomers inhibiting larger fibril formation. We showed that amyloid-β interact much 
strongly with charged (DOPG and DOTAP) than zwitterionic (DPPC). The phase of the 
bilayer is also important, such as fluid phase bilayers (DOTAP and DOPG) absorb 
peptide and become distorted easily than gel phase bilayer (DPPC).  That is due to the 
fact that in fluid phase DOPG and DOTAP film, amyloid-β inserts into the bilayer much 
easier than in gel phase DPPC. This is as a result of the electrostatic interaction between 
the peptide and lipid bilayer, and the greater fluidity of DOPG and DOTAP than DPPC. 
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4.2 Future Research 
We intend to continue our research into amyloid-β-lipid interactions. We will aim 
to gather further evidence of the difference between the two different methods of 
amyloid-β-lipid interactions: monomeric binding into bilayer and fibril binding to bilayer. 
We intend to use a combination of AFM and fluorescence microscopy to gather these 
data. 
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